Publikationen

Publikationen

Publications in PubMed: 158
Total publications: 359
Hirsch factor (h-factor, ISI): 40

Links:
Borwin Bandelow at PubMed
Borwin Bandelow at Research Gate
Borwin Bandelow at Google Scholar

Highly Cited Papers

(As of September/October 2018, this highly cited paper received enough citations to place it in the top 1% of its academic field based on a highly cited threshold for the field and publication year.)

 

Bandelow B (1995): Assessing the efficacy of treatments for panic disorder and agoraphobia. II. The Panic and Agoraphobia Scale. Int Clin Psychopharmacol 10:73-81.

Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, den Boer JA, Fineberg NA, Knapp M, Scott J, Wittchen HU, British Association for P (2005): Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 19:567-96.

Bandelow B, Zohar J, Hollander E, et al (2008b): World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders – first revision. World J Biol Psychiatry 9:248-312.

Bandelow B, Reitt M, Rover C, Michaelis S, Gorlich Y, Wedekind D (2015c): Efficacy of treatments for anxiety disorders: a meta-analysis. Int Clin Psychopharmacol 30:183-92.

Bandelow B, Baldwin D, Abelli M, et al (2017a): Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition. World J Biol Psychiatry 18:162-214.


Wissenschaftliche Publikationen/Scientific Publications

Allgulander, C., Bandelow, B., Hollander, E., Montgomery, S. A., Nutt, D. J., Okasha, A., . . . World Council of, A. (2003). WCA recommendations for the long-term treatment of generalized anxiety disorder. CNS Spectr, 8(8 Suppl 1), 53-61.

Ansorg, R., Gunesch, D., Bandelow, B., & Thomssen, R. (1977). [Differentiation and diagnostic significance of immunoglobulin classes of antibodies against cell wall antigens of yeast and mycelial phase of Candida albicans (author’s transl)]. Mykosen, 20(5), 167-177.

Baldwin, D. S., Allgulander, C., Altamura, A. C., Angst, J., Bandelow, B., den Boer, J., . . . Zohar, J. (2010). Manifesto for a European anxiety disorders research network. Eur Neuropsychopharmacol, 20(6), 426-432. doi:10.1016/j.euroneuro.2010.02.015

Baldwin, D. S., Allgulander, C., Bandelow, B., Ferre, F., & Pallanti, S. (2012). An international survey of reported prescribing practice in the treatment of patients with generalised anxiety disorder. World J Biol Psychiatry, 13(7), 510-516. doi:10.3109/15622975.2011.624548

Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., . . . Wittchen, H. U. (2014). Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol, 28(5), 403-439. doi:10.1177/0269881114525674

Baldwin, D. S., Anderson, I. M., Nutt, D. J., Bandelow, B., Bond, A., Davidson, J. R., . . . British Association for, P. (2005). Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol, 19(6), 567-596. doi:10.1177/0269881105059253

Baldwin, D. S., Bandelow, B., Dolberg, O. T., Andersen, H. F., & Stein, D. J. (2009). Symptom improvement and functional recovery in patients with anxiety disorders. European Neuropsychopharmacology, 19, S590-S591.

Baldwin, D. S., Stein, D. J., Dolberg, O. T., & Bandelow, B. (2009). How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database. Hum Psychopharmacol, 24(4), 269-275. doi:10.1002/hup.1019

Bandelow, B. Depression : Informationen für Patienten und Angehörige. [Hamburg]: DAK.

Bandelow, B. Nur nicht Bange machen lassen. Harvard-Business-Manager.

Bandelow, B. Untersuchungen zur selektiven Züchtung der Mycel- und Blastosporenphase von Candida albicans und zur diagnostischen Wertigkeit präzipitierender Antikörper gegen Antigene der beiden Wachstumsformen.

Bandelow, B. (1979). DER EINFLUSS ZENTRAL WIRKSAMER PHARMAKA AUF TESTS DER INTELEKTUELLEN LEISTUNGSFÄHIGKEIT. Göttingen: Univ.

Bandelow, B. (1985). UNTERSUCHUNG ÜBER DIE IMPULSIVITÄT VON VERHALTENSGESTÖRTEN KINDERN MIT MCD-SYNDROM, PSYCHOREAKTIV VERHALTENSGESTÖRTEN UND NICHT VERHALTENSGESTÖRTEN KINDERN. Göttingen: Univ.

Bandelow, B. (1995). Assessing the efficacy of treatments for panic disorder and agoraphobia. II. The Panic and Agoraphobia Scale. Int Clin Psychopharmacol, 10(2), 73-81. doi:10.1097/00004850-199506000-00003

Bandelow, B. (1996a). Einschränkung der Lebensqualität durch Panikstörung und Agoraphobie. Göttingen.

Bandelow, B. (1996b). Seminar social phobias – Clinical aspects and diagnosis of social phobias. Nervenheilkunde, 15(5), 315-318.

Bandelow, B. (1997). Panik- und Agoraphobie-Skala: (PAS); Handanweisung. Göttingen [u.a.]: Hogrefe.

Bandelow, B. (1998a). Therapie mit Antidepressiva. In J. Fox & E. Rüther (Eds.), Handbuch der  Arzneimitteltherapie. Band I: Psychopharmaka (pp. 65-113). Stuttgart: Thieme.

Bandelow, B. (1998b). Therapie mit Neuroleptika. In J. Fox & E. Rüther (Eds.), Handbuch der  Arzneimitteltherapie. Band I: Psychopharmaka (pp. 115-169). Stuttgart: Thieme.

Bandelow, B. (1999). Panic and Agoraphobia Scale (PAS): Manual. Seattle: Hogrefe & Huber Pub.

Bandelow, B. (2000a). [Generalized anxiety disorder]. Versicherungsmedizin, 52(3), 115-118.

Bandelow, B. (2000b). Spezielles zu den einzelnen Neuroleptika. In M. W. Möller HJ, Bandelow B. (Ed.), Neuroleptika (pp. (in press)). Stuttgart: Wissenschaftliche Verlagsgesellschaft.

Bandelow, B. (2000). Therapie mit Neuroleptika Qualitätssicherung und Arzneimittelsicherheit. Darmstadt: Steinkopff.

Bandelow, B. (2001). Panik und Agoraphobie : Diagnose, Ursachen, Behandlung. Wien [u.a.]: Springer.

Bandelow, B. (2002a). [Behavior therapy and antidepressive drugs. What helps with anxiety?]. MMW Fortschr Med, Suppl 2, 60-62, 64-65.

Bandelow, B. (2002b). How long to treat anxiety disorders? European Neuropsychopharmacology, 12, S159-S160.

Bandelow, B. (2002c). Panikstörung und Agoraphobie – Medikamentöse Behandlung. In B. Bandelow (Ed.), Angst- und Panikerkrankungen (pp. (im Druck)). Bremen: UNI-MED.

Bandelow, B. (2002d). Quick sedation of the agitated patient with zyprexa velotab – Innovation in acute psychiatric care. Nervenheilkunde, 21(5), 75-76.

Bandelow, B. (2003a). Angst- und Panikerkrankungen. Bremen: Uni-Med.

Bandelow, B. (2003b). Epidemiology of Depression and Anxiety. In S. Kasper, J. A. den Boer, & A. J. M. Sitsen (Eds.), Handbook on Depression and Anxiety (pp. 49-68). New York, N.Y.: M. Dekker.

Bandelow, B. (2003c). Panikstörung und Agoraphobie – Medikamentöse und psychotherapeutische Verfahren und Kombinationstherapie im Vergleich. In B. Bandelow (Ed.), Angst- und Panikerkrankungen (pp. 77-88). Bremen: UNI-MED.

Bandelow, B. (2003d). Soziale Phobie – Medikamentöse Therapie. In B. Bandelow (Ed.), Angst- und Panikerkrankungen (pp. 133-136). Bremen: UNI-MED.

Bandelow, B. (2003e). Soziale Phobie – Medikamentöse und psychotherapeutische Verfahren und Kombinationstherapie im Vergleich. In B. Bandelow (Ed.), Angst- und Panikerkrankungen (pp. 137-140). Bremen: UNI-MED.

Bandelow, B. (2004a). Das Angstbuch. 10. Aufl. Reinbek: Rowohlt.

Bandelow, B. (2004b). Sertraline and exposure therapy in social phobia. Br J Psychiatry, 184, 271; author reply 271-272.

Bandelow, B. (2005a). The advantages of SSRI treatment of panic disorder. Journal of Psychosomatic Research, 58(6), S23-S23.

Bandelow, B. (2005). Das Angstbuch woher Ängste kommen und wie man sie bekämpfen kann (3. Aufl ed.). Reinbek bei Hamburg: Rowohlt.

Bandelow, B. (2005b). S.2.6 Treatment of anxiety disorders. European Neuropsychopharmacology, 15, S96. doi:10.1016/s0924-977x(05)80218-4

Bandelow, B. (2005a). Treating anxiety disorders: Efficacy and safety considerations. European Psychiatry, 20, S153-S154.

Bandelow, B. (2005b). Treatment of panic anxiety disorder: An update. European Psychiatry, 20, S155.

Bandelow, B. (2006a). Angst- und Panikerkrankungen, 2. Auflage. Bremen: Uni-Med.

Bandelow, B. (2006b). C.10.01 Generalized anxiety disorder (GAD): the treatment implications of clinical heterogeneity. European Neuropsychopharmacology, 16, S579-S579. doi:10.1016/s0924-977x(06)70835-5

Bandelow, B. (2006a). Celebrities vom schwierigen Glück, berühmt zu sein (1. Aufl ed.). Reinbek bei Hamburg: Rowohlt.

Bandelow, B. (2006b). Das Angstbuch woher Ängste kommen und wie man sie bekämpfen kann (4. Aufl ed.). Reinbek bei Hamburg: Rowohlt Taschenbuch Verl.

Bandelow, B. (2006c). Defining response and remission in anxiety disorders: toward an integrated approach. CNS Spectr, 11(10 Suppl 12), 21-28.

Bandelow, B. (2006, 2. Aufl.). Celebrities – Vom schwierigen Glück, berühmt zu sein. Reinbek: Rowohlt.

Bandelow, B. (2007a). Celebrities: vom schwierigen Glück, berühmt zu sein. Reinbek bei Hamburg: Rowohlt Taschenbuch Verl.

Bandelow, B. (2007b). Das Angstbuch woher Ängste kommen und wie man sie bekämpfen kann (5. Aufl ed.). Reinbek bei Hamburg: Rowohlt Taschenbuch Verl.

Bandelow, B. (2007a). Das Buch für Schüchterne. Reinbek: Rowohlt.

Bandelow, B. (2007c). Das Buch für Schüchterne Wege aus der Selbstblockade (1. Aufl. ed.). Reinbek bei Hamburg: Rowohlt.

Bandelow, B. (2007b). Long term treatment of anxiety disorders. European Psychiatry, 22, S73. doi:10.1016/j.eurpsy.2007.01.282

Bandelow, B. (2007d). New therapy options for anxiety and compulsive disorder. Nervenarzt, 78, 510.

Bandelow, B. (2007c). Pharmacological treatment of anxiety disorders – is there a state of the art? European Psychiatry, 22, S90-S90. doi:10.1016/j.eurpsy.2007.01.1169

Bandelow, B. (2007d). Prevalence of pain in depression. International Journal of Psychiatry in Clinical Practice, 11(4), 307.

Bandelow, B. (2007e). Therapy of fear disorder. Nervenarzt, 78, 241.

Bandelow, B. (2007e). Treatment-resistant panic anxiety disorder. European Neuropsychopharmacology, 17, S207-S208.

Bandelow, B. (2008a). Celebrities (Chinese edition). Beijing: SDX Joint Publishing Company.

Bandelow, B. (2008b). Das Angstbuch (koreanische Ausgabe). Seoul: Puriwa Ipari Publishing Co.

Bandelow, B. (2008a). Das Angstbuch woher Ängste kommen und wie man sie bekämpfen kann (6. Aufl ed.). Reinbek bei Hamburg: Rowohlt Taschenbuch Verl.

Bandelow, B. (2008c). Gwiazdy. Gdansk: Gdanskie Wydawnictwo.

Bandelow, B. (2008d). The medical treatment of obsessive-compulsive disorder and anxiety. CNS Spectr, 13(9 Suppl 14), 37-46.

Bandelow, B. (2008b). The Medical Treatment of Obssessive-Compulsive Disorder and Anxiety. CNS Spectr, 13(9), 37-46.

Bandelow, B. (2008e). Recent developments in pharmacotherapy of GAD. International Journal of Neuropsychopharmacology, 11, 319-319.

Bandelow, B. (2009a). Angst-, Panik- und Zwangsstörungen. In W. D. Ludwig (Ed.), Arzneiverordnungen, 22. Auflage. ISBN 978-3-87360-015-7 (pp. 395-405): Medizinische Medien Informations GmbH.

Bandelow, B. (2009b). Angststörungen. In U. Scharmer (Ed.), Arzthandbuch – Wirtschaftliche und evidenzbasierte Arzneiverordnung für die Praxis. ISBN: 978-3-9809457-5-2 (pp. 135-137). München: Urban & Vogel.

Bandelow, B. (2009c). Benzodiazepines and Pregabalin in the Treatment of Generalized Anxiety Disorder. International Journal of Psychiatry in Clinical Practice, 13, 11-11.

Bandelow, B. (2009d). Comorbid depression and anxiety – understanding and treating complex patients. European Neuropsychopharmacology, 19, S706-S706.

Bandelow, B. (2009a). Das Angstbuch woher Ängste kommen und wie man sie bekämpfen kann (7. Aufl. ed.). Reinbek bei Hamburg: Rowohlt Taschenbuch Verl.

Bandelow, B. (2009e). [Eccentric life, early death. Borderline personality in the spotlight (interview by Dr. med. Brigitte Moreano)]. MMW Fortschr Med, 151(30-33), 6.

Bandelow, B. (2009f). Long-term treatment of anxiety disorders. International Journal of Psychiatry in Clinical Practice, 13, 19-19.

Bandelow, B. (2009b). Nur nicht Bange machen lassen – Gesundheitscoaching: Angst ist nichts Schlimmes, sie kann Manager auch beflügeln. Lernen Sie, mit negativen Gefühlen umzugehen. Harvard Business Manager, 31(12), 24.

Bandelow, B. (2010a). Rating Scales and Standardised Diagnostics in Daily Routine. European Psychiatry, 25.

Bandelow, B. (2010b). Wenn die Seele leidet. Reinbek: Rowohlt.

Bandelow, B. (2011a). Embitterment syndrome: options for psychopharmacological management. In M. Linden & A. Maercker (Eds.), Embitterment – societal, psychological, and clinical perspectives (pp. 187-196). Wien: Springer.

Bandelow, B. (2011b). EVIDENCE-BASED TREATMENT OF ANXIETY DISORDERS IN EUROPE – AN UPDATE. European Psychiatry, 26.

Bandelow, B. (2011c). Herzrasen, Atemnot, Panik. Hebammenforum(1), 7-14.

Bandelow, B. (2011d). Prominente Menschen mit Angststörungen. J  Neurol Neurochir Psychiatr, 12(4), 344-347.

Bandelow, B. (2011). Risks and Benefits of Atypical Antipsychotics in the Treatment of Generalized Anxiety Disorder (GAD). International Journal of Psychiatry in Clinical Practice, 15, 3.

Bandelow, B. (2012). Why do celebrities die young? International Journal of Psychiatry in Clinical Practice, 16, 6-7.

Bandelow, B. (2013a). The effect of comorbid anxiety on outcomes in major depressive disorder (MDD). International Journal of Psychiatry in Clinical Practice, 17, 10.

Bandelow, B. (2013b). Wer hat Angst vorm bösen Mann? warum uns Täter faszinieren (1. Aufl. ed.). Reinbek bei Hamburg: Rowohlt.

Bandelow, B. (2015). Flugangst – Woher sie kommt und wie man sie bekämpfen kann. Reinbek: Rowohlt.

Bandelow, B. (2015). Generalized Anxiety Disorder and Pain. Mod Trends Pharmacopsychiatry, 30, 153-165. doi:10.1159/000435939

Bandelow, B. (2017a). Comparison of the DSM-5 and ICD-10: panic and other anxiety disorders. CNS Spectr, 22(5), 404-406. doi:10.1017/S1092852917000116

Bandelow, B. (2017b). Panik- und Agoraphobieskala, 2. Aufl. Göttingen: Hogrefe.

Bandelow, B., & Aigner, J. M. (1998). Therapie mit klassischen und neuen Neuroleptika. Berlin [u.a.]: Springer.

Bandelow, B., Alvarez Tichauer, G., Spath, C., Broocks, A., Hajak, G., Bleich, S., & Ruther, E. (2001). Separation anxiety and actual separation experiences during childhood in patients with panic disorder. Can J Psychiatry, 46(10), 948-952. doi:10.1177/070674370104601007

Bandelow, B., Amering, M., Benkert, O., Marks, I., Nardi, A. E., Osterheider, M., . . . Versiani, M. (1996). Cardio-respiratory and other symptom clusters in panic disorder. Anxiety, 2(2), 99-101. doi:10.1002/(SICI)1522-7154(1996)2:2<99::AID-ANXI7>3.0.CO;2-8

Bandelow, B., Andersen, H. F., & Dolberg, O. T. (2007). Escitalopram in the treatment of anxiety symptoms associated with depression. Depress Anxiety, 24(1), 53-61. doi:10.1002/da.20141

Bandelow, B., Baldwin, D., Abelli, M., Altamura, C., Dell’Osso, B., Domschke, K., . . . Riederer, P. (2016). Biological markers for anxiety disorders, OCD and PTSD – a consensus statement. Part I: Neuroimaging and genetics. World J Biol Psychiatry, 17(5), 321-365. doi:10.1080/15622975.2016.1181783

Bandelow, B., Baldwin, D., Abelli, M., Bolea-Alamanac, B., Bourin, M., Chamberlain, S. R., . . . Riederer, P. (2017). Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition. World J Biol Psychiatry, 18(3), 162-214. doi:10.1080/15622975.2016.1190867

Bandelow, B., & Baldwin, D. S. (2010). Pharmacotherapy for panic disorder. In D. J. Stein, E. Hollander, & B. O. Rothbaum (Eds.), Textbook of Anxiety Disorders (pp. 399-433). Washington, D.C./London: American Psychiatric Publishing.

Bandelow, B., Baldwin, D. S., Dolberg, O. T., Andersen, H. F., & Stein, D. J. (2006). What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? J Clin Psychiatry, 67(9), 1428-1434.

Bandelow, B., Baldwin, D. S., & Domschke, K. (2014). Panic disorder and agoraphobia Oxford Psychiatry Library  Retrieved from http://lib.myilibrary.com/detail.asp?id=561294

Bandelow, B., Baldwin, D. S., & Zwanzger, P. (2013). Pharmacological Treatment of Panic Disorder. In D. S. Baldwin & B. E. Leonard (Eds.), Modern trends in pharmacopsychiatry: Anxiety Disorders (Vol. 29): Karger.

Bandelow, B., & Bassler, M. (2003). Angst- und Panikerkrankungen Ätiologie, Diagnostik, Therapie (1. Aufl ed.). Bremen [u.a.]: UNI-MED Verl.

Bandelow, B., & Bassler, M. (2006). Angst- und Panikerkrankungen Ätiologie, Diagnostik, Therapie (2. Aufl. ed.). Bremen [u.a.]: UNI-MED.

Bandelow, B., Bauer, M., Vieta, E., El-Khalili, N., Gustafsson, U., Earley, W. R., & Eriksson, H. (2014). Extended release quetiapine fumarate as adjunct to antidepressant therapy in patients with major depressive disorder: pooled analyses of data in patients with anxious depression versus low levels of anxiety at baseline. World J Biol Psychiatry, 15(2), 155-166. doi:10.3109/15622975.2013.842654

Bandelow, B., Bauer, M., Vieta, E., El-Khalili, N., Udd, M., Gustafsson, U., & Eriksson, H. (2010). Pooled analysis of the efficacy of adjunctive quetiapine XR in patients with major depressive disorder and high or low levels of baseline anxiety. International Journal of Psychiatry in Clinical Practice, 14, 19-20.

Bandelow, B., Behnke, K., Lenoir, S., Hendriks, G., Alkin, T., Dombrowski, A., & Goebel, C. (2002). Sertraline versus paroxetine in the treatment of panic disorder: A multinational randomized double-blind 15 week study. European Neuropsychopharmacology, 12, S364.

Bandelow, B., Behnke, K., Lenoir, S., Hendriks, G. J., Alkin, T., Goebel, C., & Clary, C. M. (2004). Sertraline versus paroxetine in the treatment of panic disorder: an acute, double-blind noninferiority comparison. J Clin Psychiatry, 65(3), 405-413.

Bandelow, B., Bleich, S., & Kropp, S. (2000). Handbuch Psychopharmaka (2., überarb. Aufl. ed.). Göttingen: Hogrefe.

Bandelow, B., Bleich, S., & Kropp, S. (2004a). Handbuch Psychopharmaka (2., überarb. Aufl ed.). Göttingen [u.a.]: Hogrefe.

Bandelow, B., Bleich, S., & Kropp, S. (2004b). Handbuch Psychopharmaka  Retrieved from http://ebooks.ciando.com/book/index.cfm/bok_id/4191

http://www.ciando.com/img/books/big/3801717208_k.jpg

http://www.ciando.com/img/books/3801717208_k.jpg

http://www.ciando.com/img/books/width167/3801717208_k.jpg

Bandelow, B., Bleich, S., & Kropp, S. (2012a). Handbuch Psychopharmaka (3., vollst. überarb. Aufl. ed.). Göttingen [u.a.]: Hogrefe.

Bandelow, B., Bleich, S., & Kropp, S. (2012b). Handbuch Psychopharmaka. 3., vollst. überarb. Auflage. Göttingen [u.a.]: Hogrefe.

Bandelow, B., Bleich, S., Kropp, S., & Bezchlibnyk-Butler, K. Z. (2000). Handbuch Psychopharmaka. Göttingen [u.a.]: Hogrefe.

Bandelow, B., Bobes, J., Ahokas, A., Eggens, I., Liu, S., & Brecher, M. (2007). Results from a phase III study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder. International Journal of Psychiatry in Clinical Practice, 11(4), 314-315.

Bandelow, B., Boerner, J. R., Kasper, S., Linden, M., Wittchen, H. U., & Moller, H. J. (2013a). The diagnosis and treatment of generalized anxiety disorder. Dtsch Arztebl Int, 110(17), 300-309; quiz 310. doi:10.3238/arztebl.2013.0300

Bandelow, B., Boerner, R. J., Kasper, S., Linden, M., Volz, H. P., Wittchen, H. U., & Moller, H. J. (2007). Drug treatment of generalized anxiety disorder (GAD) – a consensus statement. Psychopharmakotherapie, 14(4), 136-+.

Bandelow, B., Boerner, R. J., Kasper, S., Linden, M., Wittchen, H.-U., & Moeller, H.-J. (2013). Regular Muscle Activity Reply. Dtsch Arztebl Int, 110(37), 610-611.

Bandelow, B., Boerner, R. J., Kasper, S., Linden, M., Wittchen, H. U., & Moller, H. J. (2013b). Correspondence (reply): In reply. Dtsch Arztebl Int, 110(37), 610-611. doi:10.3238/arztebl.2013.0610c

Bandelow, B., & Brasser, M. (2009). Clinical suitability of GAD-7 scale compared to hospital anxiety and depression scale-A for monitoring treatment effects in generalized anxiety disorder. European Neuropsychopharmacology, 19, S604-S605.

Bandelow, B., & Broocks, A. (2002a). Evaluating the efficacy of psychological therapy. Verhaltenstherapie, 12(3), 205-215.

Bandelow, B., & Broocks, A. (2002b). Wirksamkeitsuntersuchungen in der Psychotherapieforschung. Verhaltenstherapie, 12(3), 205-215.

Bandelow, B., & Broocks, A. (2006). Generalisierte Angststörungen – Hypothesen zur Ätiologie. In B. Bandelow (Ed.), Angst- und Panikerkrankungen, 2. Auflage (pp. 105-108). Bremen: UNI-MED.

Bandelow, B., Broocks, A., & Hajak, G. (1995). Die Behandlung von Angsterkrankungen mit Clomipramin – eine Analyse von Kasuistiken. TW Neurologie/Psychiatrie, November, 7-9.

Bandelow, B., Broocks, A., Pekrun, G., George, A., Meyer, T., Pralle, L., . . . Ruther, E. (2000). The use of the Panic and Agoraphobia Scale (P & A) in a controlled clinical trial. Pharmacopsychiatry, 33(5), 174-181. doi:10.1055/s-2000-12982

Bandelow, B., & Broocks, B. (1997). Die medikamentöse Behandlung der sozialen Phobie. In Buchheim (Ed.), Psychotherapie und Psychopharmaka. Stuttgart/New York: Schattauer.

Bandelow, B., Brunner, E., Beinroth, D., Pralle, L., Broocks, A., Hajak, G., & Ruther, E. (1999). Application of a new statistical approach to evaluate a clinical trial with panic disorder patients. Eur Arch Psychiatry Clin Neurosci, 249(1), 21-27.

Bandelow, B., Brunner, E., Broocks, A., Beinroth, D., Hajak, G., Pralle, L., & Ruther, E. (1998). The use of the Panic and Agoraphobia Scale in a clinical trial. Psychiatry Res, 77(1), 43-49.

Bandelow, B., Charimo Torrente, A., & Rüther, E. (2004). The role of environmental factors in the etiology of social anxiety disorder. In B. Bandelow & D. J. Stein (Eds.), Social Anxiety Disorder (pp. 131-142). New York, N.Y.: Marcel Dekker.

Bandelow, B., Charimo Torrente, A., Wedekind, D., Broocks, A., Hajak, G., & Ruther, E. (2004). Early traumatic life events, parental rearing styles, family history of mental disorders, and birth risk factors in patients with social anxiety disorder. Eur Arch Psychiatry Clin Neurosci, 254(6), 397-405. doi:10.1007/s00406-004-0521-2

Bandelow, B., Chouinard, G., Bobes, J., Ahokas, A., Eggens, I., Liu, S., & Eriksson, H. (2010). Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychopharmacol, 13(3), 305-320. doi:10.1017/S1461145709990423

Bandelow, B., Degner, D., Kreusch, U., & Ruther, E. (1995). Myocarditis under therapy with clozapine. Schizophr Res, 17(3), 293-294.

Bandelow, B., Demyttenaere, K., Papakostas, G., Trivedi, M., Szamosi, J., Earley, W., & Eriksson, H. (2010). EVALUATION OF THE EFFECTS OF QUETIAPINE XR MONOTHERAPY ON SLEEP DISTURBANCE IN PATIENTS WITH MDD. European Psychiatry, 25.

Bandelow, B., & Domschke, K. (2015). Panic Disorder. In D. Stein & B. Vythilingum (Eds.), Anxiety Disorders and Gender. Cham: Springer.

Bandelow, B., Engel, K., & Wedekind, D. (2009). [Evidence-based medicine in therapy of anxiety disorders]. MMW Fortschr Med, 151(13), 89-91.

Bandelow, B., Engel, K., Wedekind, D., & Amberger, S. Neurotische, somatoforme und Belastungsstörungen : Angststörungen. Psychiatriepflege und Psychotherapie : 76 Tabellen [mit 8 Filmen auf DVD].

Bandelow, B., Falkai, P., Gruber, O., & Havemann-Reinecke, U. (2013). Kurzlehrbuch Psychiatrie (2., überarb. und akt. Aufl. ed.). Berlin [u.a.]: Springer.

Bandelow, B., Fox, J. M., & Rüther, E. (1998a). Handbuch der Arzneimitteltherapie Bd. 1 Psychopharmaka. Stuttgart [u.a.]: Thieme.

Bandelow, B., Fox, J. M., & Rüther, E. (1998b). Handbuch der Arzneimitteltherapie Bd. 1 Psychopharmaka : mit 16 Abbildungen und 117 Tabellen. Stuttgart [u.a.]: Thieme.

Bandelow, B., Fritze, J., & Rüther, E. (1998). Increased mortality in schizophrenia and the possible influence of antipsychotic treatment. Int J Psychiatry Clin Pract, 2(Suppl2), S49-S57.

Bandelow, B., Grohmann, R., & Rüther, E. (2000). Unerwünschte Begleitwirkungen der Neuroleptika und ihre Behandlung. In H. J. Möller (Ed.), Therapie psychiatrischer Erkrankungen (2 ed., pp. 217-235). Stuttgart: Thieme.

Bandelow, B., Gruber, O., & Falkai, P. (2008). Kurzlehrbuch Psychiatrie. Heidelberg: Steinkopff Verlag.

Bandelow, B., Gutermann, J., Peter, H., & Wedekind, D. (2013). Early traumatic life events, parental attitudes, family history, and birth risk factors in patients with depressive disorder and healthy controls. Int J Psychiatry Clin Pract, 17(1), 56-63. doi:10.3109/13651501.2012.735244

Bandelow, B., Hajak, G., Holzrichter, S., Kunert, H. J., & Ruther, E. (1995). Assessing the efficacy of treatments for panic disorder and agoraphobia. I. Methodological problems. Int Clin Psychopharmacol, 10(2), 83-93. doi:10.1097/00004850-199506000-00004

Bandelow, B., & Haug, T. T. (2004). Sertraline and exposure therapy in social phobia * Author’s reply. Br J Psychiatry, 184(3), 271-272.

Bandelow, B., Heise, C. A., Banaschewski, T., & Rothenberger, A. (2006). Handbuch Psychopharmaka für das Kindes- und Jugendalter. Göttingen: Hogrefe.

Bandelow, B., & Kaiya, H. (2006). Drug treatment for panic disorder. International Congress Series, 1287, 288-292.

Bandelow, B., Koch, M., Zimmermann, P., Biesold, K. H., Wedekind, D., & Falkai, P. (2012). Posttraumatic stress disorder (PTSD) in the German Armed Forces: a retrospective study in inpatients of a German army hospital. Eur Arch Psychiatry Clin Neurosci, 262(6), 459-467. doi:10.1007/s00406-012-0289-8

Bandelow, B., Krause, J., Wedekind, D., Broocks, A., Hajak, G., & Ruther, E. (2005). Early traumatic life events, parental attitudes, family history, and birth risk factors in patients with borderline personality disorder and healthy controls. Psychiatry Res, 134(2), 169-179. doi:10.1016/j.psychres.2003.07.008

Bandelow, B., & Lam, R. (2010). Escitalopram in clinical practice. ISBN 978 1 85873 439 2. London: Current Medicine Group.

Bandelow, B., Lichte, T., Rudolf, S., Wiltink, J., & Beutel, M. (2011). S3-Leitlinie Angststörungen. Heidelberg: Springer.

Bandelow, B., Lichte, T., Rudolf, S., Wiltink, J., & Beutel, M. (2015). S3-Leitlinie Angststörungen  Retrieved from http://dx.doi.org/10.1007/978-3-662-44136-7

Bandelow, B., Lichte, T., Rudolf, S., Wiltink, J., & Beutel, M. E.  Diagnostik und Therapieempfehlungen bei Angststörungen  Retrieved from http://www.aerzteblatt.de/suche?s=klinische+leitlinie+diagnostik+und+therapieempfehlungen&wo=1&wo=2

Bandelow, B., Lichte, T., Rudolf, S., Wiltink, J., & Beutel, M. E. (2014a). The diagnosis of and treatment recommendations for anxiety disorders. Dtsch Arztebl Int, 111(27-28), 473-480. doi:10.3238/arztebl.2014.0473

Bandelow, B., Lichte, T., Rudolf, S., Wiltink, J., & Beutel, M. E. (2014b). Diagnostik und Therapieempfehlungen bei Angststörungen. Dtsch Arztebl Int, 111(27-28), 473-480. doi:10.3238/arztebl.2014.0473

Bandelow, B., Lichte, T., Rudolf, S., Wiltink, J., & Beutel, M. E. (2015). The German guidelines for the treatment of anxiety disorders. Eur Arch Psychiatry Clin Neurosci, 265(5), 363-373. doi:10.1007/s00406-014-0563-z

Bandelow, B., & Linden, M. Angsterkrankungen – Panikstörung, soziale und generalisierte Angststörung (ICD-10 F4). Therapie psychischer Erkrankungen : State of the Art 2012/2013 [State of the Art-Symposien des Kongresses der Deutschen Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN) des Jahres 2012 mit dem Plus im Web Zugangscode im Buch], (2013), p. 2227-2241.

Bandelow, B., & Linden, M. Angsterkrankungen : Panikstörungen, soziale und generalisierte Angststörung (ICD-10 F4). Therapie psychischer Erkrankungen.

Bandelow, B., & Linden, M. (2009). Angsterkrankungen – Panikstörung, soziale und generalisierte Angststörung. In U. Voderholzer, F. Hohagen, & U. Kriegel (Eds.), Therapie psychischer Erkrankungen: State of the Art 2009/2010. ISBN 978-3437249013 (pp. 223-242). München: Elsevier.

Bandelow, B., & Linden, M. (2011). Angsterkrankungen – Panikstörung, soziale und generalisierte Angststörung (ICD-10 F4). In U. Voderholzer & F. Hohagen (Eds.), Therapie psychiatrischer Erkrankungen, 6. Auflage (pp. 193-208). München: Elsevier.

Bandelow, B., & Linden, M. (2013). Angsterkrankungen – Panikstörung, soziale und generalisierte Angststörung. In U. Voderholzer & F. Hohagen (Eds.), Therapie psychischer Erkrankungen: State of the Art 2012 2013 (8. Auflage) (pp. 227-241). München: Elsevier.

Bandelow, B., & Linden, M. (2014). Angsterkrankungen – Panikstörung, soziale und generalisierte Angststörung. In U. Voderholzer & F. Hohagen (Eds.), Therapie psychischer Erkrankungen: State of the Art 2014 (10. Auflage) (pp. 227-241). München: Urban & Fischer.

Bandelow, B., Lueken, U., Wolff, J., Godemann, F., Menzler, C. W., Deckert, J., . . . Berger, M. (2016). [Guideline-oriented inpatient psychiatric psychotherapeutic/psychosomatic treatment of anxiety disorders : How many personnel are need?]. Nervenarzt, 87(3), 302-310. doi:10.1007/s00115-016-0085-1

Bandelow, B., Lueken, U., Wolff, J., Godemann, F., Wolff-Menzler, C., Deckert, J., . . . Berger, M. (2017). [Erratum to: Guideline-oriented inpatient psychiatric psychotherapeutic/psychosomatic treatment of anxiety disorders. How many personnel are need?]. Nervenarzt, 88(3), 290. doi:10.1007/s00115-017-0291-5

Bandelow, B., & Margraf, J. (1994a). Empfehlungen für die Verwendung von Messinstrumenten in der klinischen Angstforschung. Fortschr Neurol Psychiatr, 62(10), 361-365.

Bandelow, B., & Margraf, J. (1994b). [Recommendations for the use of measuring instruments in clinical anxiety research]. Fortschr Neurol Psychiatr, 62(10), 361-365. doi:10.1055/s-2007-999068

Bandelow, B., & Michaelis, S. (2015). Epidemiology of anxiety disorders in the 21st century. Dialogues Clin Neurosci, 17(3), 327-335.

Bandelow, B., Michaelis, S., & Wedekind, D. (2017). Treatment of anxiety disorders. Dialogues Clin Neurosci, 19(2), 93-107.

Bandelow, B., & Muller, P. (1990). Paranoid-Hallucinatory Syndromes in Multiple-Sclerosis. Nervenheilkunde, 9(1), 18-21.

Bandelow, B., Muller, P., Frick, U., Gaebel, W., Linden, M., Muller-Spahn, F., . . . Tegeler, J. (1992). Depressive syndromes in schizophrenic patients under neuroleptic therapy. ANI Study Group Berlin, Dusseldorf, Gottingen, Munich, Federal Republic of Germany. Eur Arch Psychiatry Clin Neurosci, 241(5), 291-295. doi:10.1007/BF02195978

Bandelow, B., Muller, P., Gaebel, W., Kopcke, W., Linden, M., Muller-Spahn, F., . . . Tegeler, J. (1990). Depressive syndromes in schizophrenic patients after discharge from hospital. ANI Study Group Berlin, Dusseldorf, Gottingen, Munich. Eur Arch Psychiatry Clin Neurosci, 240(2), 113-120. doi:10.1007/BF02189981

Bandelow, B., Muller, P., & Ruther, E. (1991). [30 years experience with haloperidol]. Fortschr Neurol Psychiatr, 59(8), 297-321. doi:10.1055/s-2007-1000705

Bandelow, B., Müller, P., & Rüther, E. (1991). 30 Jahre Erfahrung mit Haloperidol. Fortschr Neurol Psychiat, 8, 297-321.

Bandelow, B., Pfeiffer, K., & Tagay, S. (2017). Angststörungen im Alter.

Bandelow, B., Reitt, M., Rover, C., Michaelis, S., Gorlich, Y., & Wedekind, D. (2015). Efficacy of treatments for anxiety disorders: a meta-analysis. Int Clin Psychopharmacol, 30(4), 183-192. doi:10.1097/YIC.0000000000000078

Bandelow, B., Rothemeyer, M., Sievert, K., Hajak, G., & Ruther, E. (1996). Panic disorder – acceptance of the diagnostic entity and treatment modalities preferred by German health professionals. Eur Psychiatry, 11(6), 298-305. doi:10.1016/S0924-9338(96)89898-1

Bandelow, B., & Ruther, E. (1997). Antipsychotic treatment: Recent developments and pharmacological principles. Psychopharmakotherapie, 4(1), 6-17.

Bandelow, B., & Ruther, E. (2004). Treatment-resistant panic disorder. CNS Spectr, 9(10), 725-739.

Bandelow, B., & Rüther, E. (1988). Neuroleptika in der Behandlung schizoaffektiver Psychosen. In M. A (Ed.), Schizoaffektive Psychosen (pp. 149-158). Berlin/ Heidelberg/ New York: Springer.

Bandelow, B., & Rüther, E. (1991). Serotonin und Depression. In H. Beckmann & M. Osterheider (Eds.), Neurotransmitter und psychische Erkrankungen. (pp. 149-158). Berlin: Springer.

Bandelow, B., & Rüther, E. (1993). Besonderheiten der Psychopharmakotherapie bei psychischen Kranken mit körperlichen Erkrankungen. In H.-J. Möller (Ed.), Therapie psychiatischer Erkrankungen. Stuttgart: Enke.

Bandelow, B., & Rüther, E. (1997). Antipsychotische Behandlung: jüngste Weiterentwicklungen und pharmakologischen Grundlagen. Psychopharmakotherapie, 4(1), 6-17.

Bandelow, B., & Rüther, E. (1998a). Anwendung von Neuroleptika bei psychischen Störungen im Rahmen internistischer Erkrankungen. In K. A. Gaebel W. (Ed.), Neuroleptika bei nicht-psychotischen Störungen (Vol. 166-174). Berlin/ Heidelberg/ New York: Springer.

Bandelow, B., & Rüther, E. (1998b). Unerwünschte Wirkungen der Neuroleptika – Extrapyramidalmotorische Wirkungen. In R. E. Bandelow B (Ed.), Therapie mit klassischen Neuroleptika – heute und morgen. Berlin/ Heidelberg/ New York: Springer.

Bandelow, B., & Rüther, E. (2000). Besonderheiten der Psychopharmaka-Therapie bei psychisch Kranken mit körperlichen Erkrankungen. In H. J. Möller (Ed.), Therapie psychiatrischer Erkrankungen (2 ed., pp. 1176-1184). Stuttgart: Thieme.

Bandelow, B., Sagebiel, A., Belz, M., Gorlich, Y., Michaelis, S., & Wedekind, D. (2018). Enduring effects of psychological treatments for anxiety disorders: meta-analysis of follow-up studies. Br J Psychiatry, 212(6), 333-338. doi:10.1192/bjp.2018.49

Bandelow, B., Sagebiel, A., Belz, M., Görlich, Y., Michaelis, S., & Wedekind, D. (2018). Authors’ reply. The British Journal of Psychiatry, 214(1), 53-54. doi:10.1192/bjp.2018.226

Bandelow, B., Saleh, K., Pauls, J., Domschke, K., Wedekind, D., & Falkai, P. (2010). Insertion/deletion polymorphism in the gene for angiotensin converting enzyme (ACE) in panic disorder: A gender-specific effect? World J Biol Psychiatry, 11(1), 66-70. doi:10.3109/15622970701459810

Bandelow, B., Schmahl, C., Falkai, P., & Wedekind, D. (2010). Borderline personality disorder: a dysregulation of the endogenous opioid system? Psychol Rev, 117(2), 623-636. doi:10.1037/a0018095

Bandelow, B., Schmahl, C., Falkai, P., & Wedekind, D. (2011). BORDERLINE PERSONALITY DISORDER – A DYSREGULATION OF THE ENDOGENOUS OPIOID SYSTEM? European Psychiatry, 26.

Bandelow, B., & Schuller, K. (2019). Mean age and gender distribution of patients with major mental disorders participating in clinical trials. Eur Arch Psychiatry Clin Neurosci. doi:10.1007/s00406-018-0972-5

Bandelow, B., Seidler-Brandler, U., Becker, A., Wedekind, D., & Ruther, E. (2007). Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders. World J Biol Psychiatry, 8(3), 175-187. doi:10.1080/15622970601110273

Bandelow, B., Sengos, G., Wedekind, D., Huether, G., Pilz, J., Broocks, A., . . . Ruther, E. (1997). Urinary excretion of cortisol, norepinephrine, testosterone, and melatonin in panic disorder. Pharmacopsychiatry, 30(4), 113-117. doi:10.1055/s-2007-979494

Bandelow, B., Sher, L., Bunevicius, R., Hollander, E., Kasper, S., Zohar, J., . . . Ptsd. (2012). Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. [Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care]. Int J Psychiatry Clin Pract, 16(2), 77-84. doi:10.3109/13651501.2012.667114

Bandelow, B., Sievert, K., Rothemeyer, M., Hajak, G., Broocks, A., & Ruther, E. (1995). [Panic disorder and agoraphobia: what is effective?]. Fortschr Neurol Psychiatr, 63(11), 451-464. doi:10.1055/s-2007-996646

Bandelow, B., Sievert, K., Rothemeyer, M., Hajak, G., Broocks, A., & Rüther, E. (1995). Panikstörung und Agoraphobie: Was wirkt? Fortschr Neurol Psychiatr, 63(11), 451-464.

Bandelow, B., Sievert, K., Röthemeyer, M., Hajak, G., Broocks, A., & Rüther, E. (1996). Panikstörung und Agoraphobie: Welche Behandlung erhalten die Patienten? Psychopharmakotherapie, (accepted for publication).

Bandelow, B., Sievert, K., Rothemeyer, M., Hajak, G., & Ruther, E. (1995). What treatments do patients with panic disorder and agoraphobia get? Eur Arch Psychiatry Clin Neurosci, 245(3), 165-171. doi:10.1007/BF02193090

Bandelow, B., Sojka, F., Broocks, A., Hajak, G., Bleich, S., & Ruther, E. (2006). Panic disorder during pregnancy and postpartum period. Eur Psychiatry, 21(7), 495-500. doi:10.1016/j.eurpsy.2005.11.005

Bandelow, B., Spath, C., Tichauer, G. A., Broocks, A., Hajak, G., & Ruther, E. (2002). Early traumatic life events, parental attitudes, family history, and birth risk factors in patients with panic disorder. Compr Psychiatry, 43(4), 269-278. doi:10.1053/comp.2002.33492

Bandelow, B., & Stein, D. J. (2004). Pharmacotherapy of social anxiety disorder. In B. Bandelow & D. J. Stein (Eds.), Social Anxiety Disorder (pp. 267-298). New York, N.Y.: Marcel Dekker.

Bandelow, B., & Stein, D. J. (2004). Social anxiety disorder. New York: Marcel Dekker.

Bandelow, B., Stein, D. J., Dolberg, O. T., Andersen, H. F., & Baldwin, D. S. (2007). Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo. Pharmacopsychiatry, 40(4), 152-156. doi:10.1055/s-2007-984398

Bandelow, B., Vieta, E., El-Khalili, N., Bauer, M., Nyberg, S., & Eriksson, H. (2011). Adjunct Quetiapine Xr in Patients with Major Depressive Disorder: A Pooled Analysis of Data from Patients with Anxious Depression. European Psychiatry, 26.

Bandelow, B., & Wedekind, D. (2006). Angst – Neurobiologie. In H. Förstl, M. Hautzinger, & G. Roth (Eds.), Neurobiologie psychischer Störungen (pp. 483-522). Heidelberg: Springer.

Bandelow, B., & Wedekind, D. (2014). [Social phobia]. Nervenarzt, 85(5), 635-644; quiz 645-637. doi:10.1007/s00115-013-3955-9

Bandelow, B., & Wedekind, D. (2015). Possible role of a dysregulation of the endogenous opioid system in antisocial personality disorder. Hum Psychopharmacol, 30(6), 393-415. doi:10.1002/hup.2497

Bandelow, B., & Wedekind, D. (2019). Network analyses to rank pharmacological treatments for generalised anxiety disorder. Lancet. doi:10.1016/S0140-6736(18)32180-9

Bandelow, B., Wedekind, D., & Leon, T. (2007). Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention. Expert Rev Neurother, 7(7), 769-781. doi:10.1586/14737175.7.7.769

Bandelow, B., Wedekind, D., Pauls, J., Broocks, A., Hajak, G., & Ruther, E. (2000). Salivary cortisol in panic attacks. Am J Psychiatry, 157(3), 454-456. doi:10.1176/appi.ajp.157.3.454

Bandelow, B., Wedekind, D., Sandvoss, V., Broocks, A., Hajak, G., Pauls, J., . . . Ruther, E. (2000). Diurnal variation of cortisol in panic disorder. Psychiatry Res, 95(3), 245-250.

Bandelow, B., Wiltink, J., Alpers, G. W., Benecke, C., Deckert, J., Eckhardt-Henn, A., . . . Beutel, M. E. (2014). S3-Leitlinie zur Behandlung von Angststörungen.   Retrieved from www.awmf.org/leitlinien.html

Bandelow, B., Wolff-Menzler, C., Wedekind, D., & Ruther, E. (2006). Anxiety disorders: Long-term treatment and relapse prevention. Mmw-Fortschritte Der Medizin, 148(4), 31-34.

Bandelow, B., Wolff-Menzler, C., Wedekind, D., & Rüther, E. (2006). Patienten mit Angst- und Panikstörungen – Wie lange muss behandelt werden? MMW-Fortschr.Med., 148, 31-34.

Bandelow, B., & World Federation of Societies of Biological Psychiatry. (2005). Medikamentöse Behandlung von Angst- und Zwangs- und posttraumatischen Belastungsstörungen : Behandlungsleitlinien der World Federation of Societies of Biological Psychiatry (WFSBP). Stuttgart: Wiss. Verl.-Ges.

Bandelow, B., Zohar, J., Hollander, E., Kasper, S., & Möller, H. J. (2005). Leitlinien der World Federation of Societies of Biological Psychiatry (WFSBP) für die medikamentöse Behandlung von Angst-, Zwangs- und posttraumatischen Belastungsstörungen. Stuttgart: Wissenschaftliche Verlagsgesellschaft.

Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Moller, H. J., Wfsbp Task Force on Treatment Guidelines for Anxiety, O.-C., . . . Vega, J. (2008). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders – first revision. World J Biol Psychiatry, 9(4), 248-312. doi:10.1080/15622970802465807

Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Moller, H. J., World Federation of Societies of Biological Psychiatry Task Force on Treatment Guidelines for Anxiety, O.-C., & Posttraumatic Stress, D. (2002). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J Biol Psychiatry, 3(4), 171-199. doi:10.3109/15622970209150621

Bandelow, B., Zohar, J., Kasper, S., & Moller, H. J. (2008). How to grade categories of evidence. World J Biol Psychiatry, 9(4), 242-247. doi:10.1080/15622970802456590

Bleich, S., Bandelow, B., Javaheripour, K., Muller, A., Degner, D., Wilhelm, J., . . . Kornhuber, J. (2003). Hyperhomocysteinemia as a new risk factor for brain shrinkage in patients with alcoholism. Neurosci Lett, 335(3), 179-182.

Bleich, S., Degner, D., Bandelow, B., von Ahsen, N., Ruther, E., & Kornhuber, J. (2000). Plasma homocysteine is a predictor of alcohol withdrawal seizures. Neuroreport, 11(12), 2749-2752.

Bleisch, B., Bandelow, B., & Gmür, A. Sternstunde Philosophie 2015.03.01 […].

Broocks, A., & Bandelow, B. (1999a). Drs. Broocks and Bandelow Reply. Am J Psychiatry, 156(7), 1129a-1130.

Broocks, A., & Bandelow, B. (1999b). Fetal alcohol exposure and adult psychiatric disorders – Dr. Broocks and Bandelow reply. American Journal of Psychiatry, 156(7), 1129-1130.

Broocks, A., Bandelow, B., George, A., Jestrabeck, C., Opitz, M., Bartmann, U., . . . Hajak, G. (2000). Increased psychological responses and divergent neuroendocrine responses to m-CPP and ipsapirone in patients with panic disorder. Int Clin Psychopharmacol, 15(3), 153-161. doi:10.1097/00004850-200015030-00004

Broocks, A., Bandelow, B., George, A., & Roed, I. (2001). Increased psychobehavioral responsiveness to M-chlorophenylpiperazine (m-CPP) and ipsapirone (IPS) in patients with panic disorder (PDA). Journal of Neurochemistry, 78, 81.

Broocks, A., Bandelow, B., Koch, K., Bartmann, U., Kinkelbur, J., Schweiger, U., . . . Hajak, G. (2002). Smoking modulates neuroendocrine responses to ipsapirone in patients with panic disorder. Neuropsychopharmacology, 27(2), 270-278. doi:10.1016/S0893-133X(02)00298-1

Broocks, A., Bandelow, B., Pekrun, G., George, A., Meyer, T., Bartmann, U., . . . Ruther, E. (1998). Comparison of aerobic exercise, clomipramine, and placebo in the treatment of panic disorder. Am J Psychiatry, 155(5), 603-609. doi:10.1176/ajp.155.5.603

Broocks, A., Junghanns, K., Thiel, A., Gleiter, C. H., & Bandelow, B. (2000a). Advances in the pharmacotherapy of depression by new antidepressants. Fortschritte Der Neurologie Psychiatrie, 68(1), 17-24.

Broocks, A., Junghanns, K., Thiel, A., Gleiter, C. H., & Bandelow, B. (2000b). [New antidepressive drugs in comparison with classical tricyclics. Mechanism of action and clinical evaluation]. Fortschr Neurol Psychiatr, 68(1), 17-24. doi:10.1055/s-2000-11639

Broocks, A., Meyer, T., George, A., Hillmer-Vogel, U., Meyer, D., Bandelow, B., . . . Ruther, E. (1999). Decreased neuroendocrine responses to meta-chlorophenylpiperazine (m-CPP) but normal responses to ipsapirone in marathon runners. Neuropsychopharmacology, 20(2), 150-161. doi:10.1016/S0893-133X(98)00056-6

Broocks, A., Meyer, T., Gleiter, C. H., Hillmer-Vogel, U., George, A., Bartmann, U., & Bandelow, B. (2001). Effect of aerobic exercise on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine and to ipsapirone in untrained healthy subjects. Psychopharmacology (Berl), 155(3), 234-241.

Broocks, A., Meyer, T., Opitz, M., Bartmann, U., Hillmer-Vogel, U., George, A., . . . Bandelow, B. (2003). 5-HT1A responsivity in patients with panic disorder before and after treatment with aerobic exercise, clomipramine or placebo. Eur Neuropsychopharmacol, 13(3), 153-164. doi:10.1016/S0924-977X(02)00177-3

Broocks, A., Meyer, T. F., Bandelow, B., George, A., Bartmann, U., Ruther, E., & Hillmer-Vogel, U. (1997). Exercise avoidance and impaired endurance capacity in patients with panic disorder. Neuropsychobiology, 36(4), 182-187. doi:10.1159/000119381

Broocks, A., Meyer, T. F., George, A., Pekrun, G., Hillmer-Vogel, U., Hajak, G., . . . Ruther, E. (1997). [Value of sports in treatment of psychiatric illness]. Psychother Psychosom Med Psychol, 47(11), 379-393.

Broocks, A., Meyer, T. F., George, A., Pekrun, G., HillmerVogel, U., Hajak, G., . . . Ruther, E. (1997). The role of exercise in the treatment of psychiatric disorders. Psychotherapie Psychosomatik Medizinische Psychologie, 47(11), 379-393.

Broocks, A., Peters, M., Bandelow, B., & Ruther, E. (1999). Physical activity and affective diseases. Verhaltenstherapie, 9, 7-8.

Broocks, A., Rüther, E., Munzel, U., Hajak, G., Wedekind, D., & Bandelow, B. (2000). FC04.01 Responsiveness of central serotonin receptors in panic disorder: Effects of clomipramine treatment and exercise. European Psychiatry, 15, 243s-243s. doi:10.1016/s0924-9338(00)94044-6

Buchheim, P., & Bandelow, B. (1997). Psychotherapie und Psychopharmaka : störungsorientierte Behandlungsansätze – kombinierte Therapie. Stuttgart [u.a.]: Schattauer.

Bundesgesetzblatt. (2008). Anlage „Versorgungsmedizinische Grundsätze“. Anlageband zum Bundesgesetzblatt Teil I Nr. 57 vom 15. Dezember 2008. Anlage zu § 2 der Versorgungsmedizin-Verordnung vom 10. Dezember 2008. 1. bis 5. Verordnung zur Änderung der Versorgungsmedizin-Verordnung vom 11.10.2012 (Anlage zum Bundesgesetzblatt Teil I Nr. 57 vom 15. Dezember 2008 sowie Bundesgesetzblatt Teil I Nr. 47 vom 16.10.2012).

Degner, D., Bandelow, B., Akkan, R., Kropp, S., Nietmann, P. D., Ruther, E., & Bleich, S. (2003). Relevance of therapeutic drug monitoring (TDM) in patients with quetiapine administration. Pharmacopsychiatry, 36(5), 219-219.

Degner, D., Bleich, S., Grohmann, R., Bandelow, B., & Ruther, E. (2000). Myocarditis associated with clozapine treatment. Aust N Z J Psychiatry, 34(5), 880. doi:10.1080/j.1440-1614.2000.0822n.x

Degner, D., Fiege, O., Bandelow, B., Grohmann, R., & Ruther, E. (2005). Oculogyric crisis under aripiprazol in combination with fluoxetin. Psychopharmakotherapie, 12(1), 32-33.

Degner, D., Knievel, A., Muller, P., Bandelow, B., Schaefer, E., Grohmann, R., & Ruther, E. (2004). Acute agranulocytosis after long-term clozapine treatment. Psychopharmakotherapie, 11(3), 98-100.

Degner, D., Knievel, A., Müller, P., Bandelow, B., Schaefer, E., Grohmann, R., & Rüther, E. (2004). Akute Agranulozytose nach langjähriger Clozapinbehandlung. Psychopharmakotherapie, 11, 98-100.

Doering, S., Wedekind, D., Pilz, J., Bandelow, B., Adler, L., & Huether, G. (2001). [Cortisol in night-urine: Introduction of a research method in psychoneuroendocrinology]. Z Psychosom Med Psychother, 47(1), 42-57.

Domschke, K., Hohoff, C., Jacob, C., Maier, W., Fritze, J., Bandelow, B., . . . Deckert, J. (2008). Chromosome 4q31-34 panic disorder risk locus: association of neuropeptide Y Y5 receptor variants. Am J Med Genet B Neuropsychiatr Genet, 147B(4), 510-516. doi:10.1002/ajmg.b.30629

Domschke, K., Reif, A., Weber, H., Richter, J., Hohoff, C., Ohrmann, P., . . . Deckert, J. (2011). Neuropeptide S receptor gene — converging evidence for a role in panic disorder. Mol Psychiatry, 16(9), 938-948. doi:10.1038/mp.2010.81

DRV. (2012). Leitfaden für die sozialmedizinische Begutachtung  – Deutsche Rentenversicherung: Deutsche Rentenversicherung.

Engel, K., Bandelow, B., Gruber, O., & Wedekind, D. (2009). Neuroimaging in anxiety disorders. J Neural Transm (Vienna), 116(6), 703-716. doi:10.1007/s00702-008-0077-9

Engel, K. R., Bandelow, B., Neumann, C., Obst, K., & Wedekind, D. (2012). Disorder-specific emotional imagery for differential and quantitative assessment of agoraphobia. Curr Pharm Des, 18(35), 5638-5644.

Engel, K. R., Obst, K., Bandelow, B., Dechent, P., Gruber, O., Zerr, I., . . . Wedekind, D. (2016). Functional MRI activation in response to panic-specific, non-panic aversive, and neutral pictures in patients with panic disorder and healthy controls. Eur Arch Psychiatry Clin Neurosci, 266(6), 557-566. doi:10.1007/s00406-015-0653-6

Erhardt, A., Czibere, L., Roeske, D., Lucae, S., Unschuld, P. G., Ripke, S., . . . Binder, E. B. (2011). TMEM132D, a new candidate for anxiety phenotypes: evidence from human and mouse studies. Mol Psychiatry, 16(6), 647-663. doi:10.1038/mp.2010.41

Erhardt, A., Lucae, S., Kern, N., Unschuld, P. G., Ising, M., Lieb, R., . . . Holsboer, F. (2008). Association of polymorphisms in the angiotensin-converting enzyme gene with syndromal panic attacks. Mol Psychiatry, 13(3), 242-243. doi:10.1038/sj.mp.4002094

Fritze, J., & Bandelow, B. (1998a). The QT-interval and the new, atypical neuroleptic sertindole. Psychopharmakotherapie, 5(3), 115-120.

Fritze, J., & Bandelow, B. (1998b). The QT interval and the atypical antipsychotic, sertindole. Int J Psychiatry Clin Pract, 2(4), 265-273. doi:10.3109/13651509809115372

Gade, K., Haussinger, C., & Bandelow, B. (2009). Atypical anorexia in a male patient accompanied by strong obsessive-compulsive symptoms successfully treated with naltrexone. Pharmacopsychiatry, 42(4), 164-165. doi:10.1055/s-0028-1128114

Greist, J. H., Bandelow, B., Hollander, E., Marazziti, D., Montgomery, S. A., Nutt, D. J., . . . World Council of, A. (2003). WCA recommendations for the long-term treatment of obsessive-compulsive disorder in adults. CNS Spectr, 8(8 Suppl 1), 7-16.

Hajak, G., & Bandelow, B. (1992). Angst und Schlafstörungen. München: Medizin Verlag.

Hajak, G., & Bandelow, B. (1994). Pharmacotherapy of Insomnia in General-Practice. Medizinische Welt, 45(6), 258-263.

Hajak, G., & Bandelow, B. (1996). [Coincidence of anxiety and sleep disorders. Overview and case reports]. Fortschr Neurol Psychiatr, 64(1), 26-40. doi:10.1055/s-2007-996370

Hajak, G., & Bandelow, B. (1998). Safety and tolerance of zolpidem in the treatment of disturbed sleep: a post-marketing surveillance of 16944 cases. Int Clin Psychopharmacol, 13(4), 157-167.

Hajak, G., Bandelow, B., Zulley, J., & Pittrow, D. (2002). “As needed” pharmacotherapy combined with stimulus control treatment in chronic insomnia–assessment of a novel intervention strategy in a primary care setting. Ann Clin Psychiatry, 14(1), 1-7.

Hajak, G., Clarenbach, P., Fischer, W., Haase, W., Bandelow, B., Adler, L., & Ruther, E. (1995). Effects of hypnotics on sleep quality and daytime well-being. Data from a comparative multicentre study in outpatients with insomnia. Eur Psychiatry, 10 Suppl 3, 173s-179s. doi:10.1016/0924-9338(96)80100-3

Hajak, G., Clarenbach, P., Fischer, W., Rodenbeck, A., Bandelow, B., Broocks, A., & Ruther, E. (1998). Rebound insomnia after hypnotic withdrawal in insomniac outpatients. Eur Arch Psychiatry Clin Neurosci, 248(3), 148-156.

Hajak, G., Rodenbeck, A., Adler, L., Huether, G., Bandelow, B., Herrendorf, G., . . . Ruther, E. (1996). Nocturnal melatonin secretion and sleep after doxepin administration in chronic primary insomnia. Pharmacopsychiatry, 29(5), 187-192. doi:10.1055/s-2007-979569

Hajak, G., Rodenbeck, A., Bandelow, B., Friedrichs, S., Huether, G., & Ruther, E. (1996). Nocturnal plasma melatonin levels after flunitrazepam administration in healthy subjects. Eur Neuropsychopharmacol, 6(2), 149-153. doi:10.1016/0924-977X(96)00005-3

Hajak, G., Rodenbeck, A., Herrendorf, G., Staedt, J., Bandelow, B., Huether, G., & Rüther, E. Reduced nocturnal melatonin plasma concentration in patients with chronic primary insomnia. Pineal Res, in press.

Hajak, G., Rodenbeck, A., Staedt, J., Bandelow, B., Huether, G., & Ruther, E. (1995). Nocturnal plasma melatonin levels in patients suffering from chronic primary insomnia. J Pineal Res, 19(3), 116-122.

Hasan, A., Bandelow, B., Yatham, L. N., Berk, M., Falkai, P., Moller, H. J., . . . Chairs, W. G. T. F. (2018). WFSBP guidelines on how to grade treatment evidence for clinical guideline development. World J Biol Psychiatry, 1-28. doi:10.1080/15622975.2018.1557346

Haug, B. A., Hermsteiner, E. M., Bandelow, B., & Paulus, W. (1997). Parallel increase of heterochromatic increment threshold and postadaptation thresholds in Parkinson’s disease and in neuroleptic treatment. Vision Res, 37(24), 3535-3547. doi:10.1016/S0042-6989(97)00089-8

Heindl, S., Binder, C., Desel, H., Matthies, U., Lojewski, I., Bandelow, B., . . . Chemnitius, J. M. (2000). [Etiology of initially unexplained confusion of excitability in deadly nightshade poisoning with suicidal intent. Symptoms, differential diagnosis, toxicology and physostigmine therapy of anticholinergic syndrome]. Dtsch Med Wochenschr, 125(45), 1361-1365. doi:10.1055/s-2000-8178

Hohoff, C., Jung, A., Freitag, C. M., Willis-Owen, S. A., Ponath, G., Krakowitzky, P., . . . Deckert, J. (2005). Investigation of RGS2 and RGS13 gene polymorphisms in human panic disorder (Poster abstract). American Journal of Medical Genetics Part B-Neuropsychiatric Genetics, 138b(1), 11-11.

Hohoff, C., Mullings, E. L., Heatherley, S. V., Freitag, C. M., Neumann, L. C., Domschke, K., . . . Deckert, J. (2010). Adenosine A(2A) receptor gene: evidence for association of risk variants with panic disorder and anxious personality. J Psychiatr Res, 44(14), 930-937. doi:10.1016/j.jpsychires.2010.02.006

Hohoff, C., Neumann, A., Domschke, K., Jacob, C., Maier, W., Fritze, J., . . . Deckert, J. (2009). Association analysis of Rgs7 variants with panic disorder. J Neural Transm (Vienna), 116(11), 1523-1528. doi:10.1007/s00702-008-0097-5

Hohoff, C., Weber, H., Richter, J., Domschke, K., Zwanzger, P. M., Ohrmann, P., . . . Deckert, J. (2015). RGS2 ggenetic variation: association analysis with panic disorder and dimensional as well as intermediate phenotypes of anxiety. Am J Med Genet B Neuropsychiatr Genet, 168B(3), 211-222. doi:10.1002/ajmg.b.32299

Kasper, S., Herman, B., Nivoli, G., Van Ameringen, M., Petralia, A., Mandel, F. S., . . . Bandelow, B. (2009). Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. Int Clin Psychopharmacol, 24(2), 87-96.

Keck, M. E., Kern, N., Erhardt, A., Unschuld, P. G., Ising, M., Salyakina, D., . . . Binder, E. B. (2008). Combined effects of exonic polymorphisms in CRHR1 and AVPR1B genes in a case/control study for panic disorder. Am J Med Genet B Neuropsychiatr Genet, 147B(7), 1196-1204. doi:10.1002/ajmg.b.30750

Klöppel, S., Jessen, F., Albus, C., Assion, H.-J., & Bandelow, B. (2017). Praxishandbuch Gerontopsychiatrie und -psychotherapie Diagnostik und Therapie im höheren Lebensalter (1. Auflage ed.).

Kronenberg, G., Berger, P., Tauber, R. F., Bandelow, B., Henkel, V., & Heuser, I. (2005). Randomized, double-blind study of SR142801 (Osanetant). A novel neurokinin-3 (NK3) receptor antagonist in panic disorder with pre- and posttreatment cholecystokinin tetrapeptide (CCK-4) challenges. Pharmacopsychiatry, 38(1), 24-29. doi:10.1055/s-2005-837768

Leygraf, A., Hohoff, C., Freitag, C., Willis-Owen, S. A., Krakowitzky, P., Fritze, J., . . . Deckert, J. (2006). Rgs 2 gene polymorphisms as modulators of anxiety in humans? J Neural Transm (Vienna), 113(12), 1921-1925. doi:10.1007/s00702-006-0484-8

Linden, M., Bandelow, B., Boerner, R. J., Brasser, M., Kasper, S., Moller, H. J., . . . Wittchen, H. U. (2013). The best next drug in the course of generalized anxiety disorders: the “PN-GAD-algorithm”. Int J Psychiatry Clin Pract, 17(2), 78-89. doi:10.3109/13651501.2012.722645

Link, S., Paulus, W., & Bandelow, B. (2009). Remission of acute psychotic anxious depression in a patient with Parkinson’s disease after treatment with quetiapine. Mov Disord, 24(16), 2431-2432. doi:10.1002/mds.22846

Madhukar, H. T., Bandelow, B., Demyttenaere, K., Papakostas, G., I, Szamosi, J., Earley, W., & Eriksson, H. (2015). Erratum. Int J Neuropsychopharmacol, 18(9). doi:10.1093/ijnp/pyv056

Margraf, J., & Bandelow, B. (1997). Recommendations on assessment instruments for clinical research. Zeitschrift Fur Klinische Psychologie-Forschung Und Praxis, 26(2), 150-156.

Meiser, M., Dupper, F., Wedekind, D., & Bandelow, B. (2015). Improvement of Borderline Personality Disorder with Naltrexone: Results of a Retrospective Evaluation. European Psychiatry, 30.

Meyer, T., Broocks, A., Bandelow, B., Hillmer-Vogel, U., & Ruther, E. (1998). Endurance training in panic patients: spiroergometric and clinical effects. Int J Sports Med, 19(7), 496-502. doi:10.1055/s-2007-971951

Möller, H.-J., & Bandelow, B. (2002). Moderne Antidepressiva : 31 Tabellen. Stuttgart [u.a.]: Thieme.

Möller, H.-J., & Bandelow, B. (2006). Innovation und Wandel der antidepressiven Therapie in Deutschland : 24 Tab. Stuttgart [u.a.]: Thieme.

Möller, H.-J., Müller, W. E., & Bandelow, B. (2001). Neuroleptika : pharmakologische Grundlagen, klinisches Wissen und therapeutisches Vorgehen ; mit 136 Tabellen. Stuttgart: Wiss. Verl.-Ges.

Moller, H. J., Angermeyer, M. C., Bandelow, B., Deuschle, M., Kissling, W., Linden, M., . . . Voderholzer, U. (2007). Compliance in schizophrenia and comparable psychotic disorders. Psychopharmakotherapie, 14(1), 14-22.

Moller, H. J., Bandelow, B., Bauer, M., Hampel, H., Herpertz, S. C., Soyka, M., . . . Maier, W. (2015a). DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences–part 1: general aspects and paradigmatic discussion of depressive disorders. Eur Arch Psychiatry Clin Neurosci, 265(1), 5-18. doi:10.1007/s00406-014-0520-x

Moller, H. J., Bandelow, B., Bauer, M., Hampel, H., Herpertz, S. C., Soyka, M., . . . Maier, W. (2015b). DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences-part 2: bipolar disorders, schizophrenia spectrum disorders, anxiety disorders, obsessive-compulsive disorders, trauma- and stressor-related disorders, personality disorders, substance-related and addictive disorders, neurocognitive disorders. Eur Arch Psychiatry Clin Neurosci, 265(2), 87-106. doi:10.1007/s00406-014-0521-9

Moller, H. J., Bandelow, B., Volz, H. P., Barnikol, U. B., Seifritz, E., & Kasper, S. (2016). The relevance of ‘mixed anxiety and depression’ as a diagnostic category in clinical practice. Eur Arch Psychiatry Clin Neurosci, 266(8), 725-736. doi:10.1007/s00406-016-0684-7

Moller, H. J., Brasser, M., Kasper, S., Volz, H. P., Boerner, R. J., & Bandelow, B. (2009). Effectiveness and tolerability of pregabalin in patients with generalized anxiety disorders in routine clinical care. Psychopharmakotherapie, 16(5), 211-+.

Möller, H. J., Brasser, M., Kasper, S., Volz, H. P., Boerner, R. J., & Bandelow, B. (2009). Wirksamkeit und Verträglichkeit von Pregabalin bei Patienten mit generalisierten Angststörungen in der täglichen Praxis. Psychopharmakotherapie, 16(5), 211-217.

Möller, H. J., Müller, W. E., & Bandelow, B. (2000). Neuroleptika. Stuttgart: Wissenschaftliche Verlagsgesellschaft.

Muller, P., Bandelow, B., Gaebel, W., Kopcke, W., Linden, M., Muller-Spahn, F., . . . Tegeler, J. (1992). Intermittent medication, coping and psychotherapy. Interactions in relapse prevention and course modification. Br J Psychiatry Suppl(18), 140-144.

Muller, P., Gaebel, W., Bandelow, B., Kopcke, W., Linden, M., Muller-Spahn, F., . . . Tegeler, J. (1998a). [The social status of schizophrenic patients]. Nervenarzt, 69(3), 204-209.

Muller, P., Gaebel, W., Bandelow, B., Kopcke, W., Linden, M., Muller-Spahn, F., . . . Tegeler, J. (1998b). Zur sozialen Situation schizophrener Patienten. Der Nervenarzt, 69(3), 204-209. doi:10.1007/s001150050261

Munzel, U., & Bandelow, B. (1998). The use of parametric vs. nonparametric tests in the statistical evaluation of rating scales. Pharmacopsychiatry, 31(6), 222-224. doi:10.1055/s-2007-979332

Muscatello, M. R., Spina, E., Bandelow, B., & Baldwin, D. S. (2012). Clinically relevant drug interactions in anxiety disorders. Hum Psychopharmacol, 27(3), 239-253. doi:10.1002/hup.2217

Naber, D., Bandelow, B., Bender, S., Klimke, A., Kuhn, K., Lambert, M., . . . Dittmann, R. W. (2001). Subjective well-being under neuroleptic treatment with olanzapine versus clozapine: First results from a double-blind clinical trial using the SWN self-rating scale. Schizophr Res, 49(1-2), 240-240.

Naber, D., Riedel, M., Klimke, A., Vorbach, E. U., Lambert, M., Kuhn, K. U., . . . Dittmann, R. W. (2005). Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia. Acta Psychiatr Scand, 111(2), 106-115. doi:10.1111/j.1600-0447.2004.00486.x

Neumann, M.-C., Bandelow, B., Bandelow, B., & Fuchs, E. Störungsspezifische, visuelle emotionale Stimuli bei der Agoraphobie mit Panikstörung.

Papakostas, G., Bandelow, B., Demyttenaere, K., Trivedi, M., Earley, W., Szamosi, J., & Eriksson, H. (2010). Efficacy of extended release quetiapine fumarate (quetiapine XR) monotherapy on sleep disturbance in patients with major depressive disorder. International Journal of Neuropsychopharmacology, 13, 159-159.

Passie, T., Schneider, U., Borsutzky, M., Breyer, R., Emrich, H. M., Bandelow, B., & Schmid-Ott, G. (2013). Impaired perceptual processing and conceptual cognition in patients with anxiety disorders: a pilot study with the binocular depth inversion paradigm. Psychol Health Med, 18(3), 363-374. doi:10.1080/13548506.2012.722649

Pauls, J., Bandelow, B., Ruther, E., & Kornhuber, J. (2000). Polymorphism of the gene of angiotensin converting enzyme: lack of association with mood disorder. J Neural Transm (Vienna), 107(11), 1361-1366. doi:10.1007/s007020070023

Paulus, W., Hermsteiner, E., Haug, B., & Bandelow, B. (1995). Increment Threshold and Postadaptation Threshold Are Increased in Parkinsons-Disease. Investigative Ophthalmology & Visual Science, 36(4), S227-S227.

Peter, H., Bandelow, B., & Krausz, M. (1998). [The impact of the central serotonin system on alcoholism and therapeutic consequences]. Fortschr Neurol Psychiatr, 66(10), 459-465. doi:10.1055/s-2007-995285

Pollack, M. H., Allgulander, C., Bandelow, B., Cassano, G. B., Greist, J. H., Hollander, E., . . . World Council of, A. (2003). WCA recommendations for the long-term treatment of panic disorder. CNS Spectr, 8(8 Suppl 1), 17-30.

Prange, H., Bandelow, B., & Prange, B. (2002). Notfallbuch Neurologie : vom Syndrom zur Therapie ; mit 177 Tabellen. Stuttgart: Wiss. Verl.-Ges.

Reimers, C. D., & Bandelow, B. (2003). Neurologie, Psychiatrie und Sport : 48 Tabellen. Stuttgart [u.a.]: Thieme.

Remmel, A., & Bandelow, B. (2006). Handbuch Körper und Persönlichkeit : Entwicklungspsychologie, Neurobiologie und Therapie von Persönlichkeitsstörungen ; mit 53 Tabellen. Stuttgart [u.a.]: Schattauer.

Sandmann, J., Lorch, B., Bandelow, B., Hartter, S., Winter, P., Hiemke, C., & Benkert, O. (1998). Fluvoxamine or placebo in the treatment of panic disorder and relationship to blood concentrations of fluvoxamine. Pharmacopsychiatry, 31(4), 117-121. doi:10.1055/s-2007-979311

Schreier, E., Bandelow, B., Mausberg, R., & Nitsche, M.  Die Wirkung der EKT bei pharmakoresistenten affektiven und schizophreniformen Störungen  Retrieved from http://hdl.handle.net/11858/00-1735-0000-0001-BBDE-2

http://nbn-resolving.de/urn:nbn:de:gbv:7-11858/00-1735-0000-0001-BBDE-2-8

http://d-nb.info/1044769718/34

Schubert, K., & Bandelow, N. C. (2014). Lehrbuch der Politikfeldanalyse Lehr- und Handbücher der Politikwissenschaft  Retrieved from http://www.degruyter.com/search?f_0=isbnissn&q_0=9783110408072&searchTitles=true

http://www.degruyter.com/doi/book/10.1515/9783110408072

http://www.degruyter.com/doc/cover/9783110408072.jpg

Sehmer-Kurz, K., Stiens, G., & Bandelow, B. (2006). Therapie der Depression und Angst im Alter. Der Neurologe und Psychiater, 31-38.

SIMEN, S., HAJAK, G., SCHLAF, G., WESTENHOFER, J., RODENBECK, A., BANDELOW, B., . . . RUTHER, E. (1995). CHRONIC SLEEP COMPLAINTS – RESULTS OF A REPRESENTATIVE SURVEY IN GERMANY. Nervenarzt, 66(9), 686-695.

Simen, S., Hajak, G., Schlaf, G., Westenhofer, J., Rodenbeck, A., Bandelow, B., . . . Ruther, E. (1995). [Chronification of sleep disorders. Results of a representative survey in West Germany]. Nervenarzt, 66(9), 686-695.

Sprute, A. J., & Bandelow, B.  Eine Untersuchung zur Wirkung von Paroxetin versus Placebo in Kombination mit regelmäßigem Ausdauertraining oder Entspannungstraining auf den Kortisolwert im Nachturin von Patienten mit einer Panikstörung mit und ohne Agoraphobie  Retrieved from http://hdl.handle.net/11858/00-1735-0000-000D-F24E-F

http://nbn-resolving.de/urn:nbn:de:gbv:7-webdoc-2276-7

http://d-nb.info/1044074094/34

http://creativecommons.org/licenses/by-nc-nd/3.0/

Stein, D., Kalali, A., Bandelow, B., Katzman, M. A., Olausson, B., & Eriksson, H. (2010). Efficacy of extended release quetiapine fumarate monotherapy in patients with generalised anxiety disorder : Results from 5 placebo-controlled trials. International Journal of Neuropsychopharmacology, 13, 118-119.

Stein, D. J., Andersen, E. W., & Overo, K. F. (2007). Response of symptom dimensions in obsessive-compulsive disorder to treatment with citalopram or placebo. Braz J Psychiatry, 29(4), 303-307.

Stein, D. J., Baldwin, D. S., Bandelow, B., Blanco, C., Fontenelle, L. F., Lee, S., . . . van Ameringen, M. (2010). A 2010 evidence-based algorithm for the pharmacotherapy of social anxiety disorder. Curr Psychiatry Rep, 12(5), 471-477. doi:10.1007/s11920-010-0140-8

Stein, D. J., Baldwin, D. S., Dolberg, O., Despiegel, N., & Bandelow, B. (2006). P.4.d.002 Which factors predict placebo response in anxiety disorders and major depression? European Neuropsychopharmacology, 16, S468. doi:10.1016/s0924-977x(06)70618-6

Stein, D. J., Baldwin, D. S., Dolberg, O. T., Despiegel, N., & Bandelow, B. (2006). Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram. J Clin Psychiatry, 67(11), 1741-1746.

Stein, D. J., Baldwin, D. S., Dolberg, O. T., Despiegel, N., & Bandelow, B. (2007). More on placebo response – Reply. Journal of Clinical Psychiatry, 68(12), 1984-1985.

Stein, D. J., & Bandelow, B. (2004). Future Directions. In B. Bandelow & D. J. Stein (Eds.), Social Anxiety Disorder (pp. 335-344). New York: Marcel Dekker.

Stein, D. J., Bandelow, B., Dolberg, O. T., Andersen, H. F., & Baldwin, D. S. (2008). How are symptom severity and functional recovery/relapse related? An analysis of the escitalopram database. European Psychiatry, 23, S369-S369.

Stein, D. J., Bandelow, B., Dolberg, O. T., Andersen, H. F., & Baldwin, D. S. (2009). Anxiety symptom severity and functional recovery or relapse. Ann Clin Psychiatry, 21(2), 81-88.

Stein, D. J., Bandelow, B., Hollander, E., Nutt, D. J., Okasha, A., Pollack, M. H., . . . World Council of, A. (2003). WCA Recommendations for the long-term treatment of posttraumatic stress disorder. CNS Spectr, 8(8 Suppl 1), 31-39.

Stein, D. J., Bandelow, B., Merideth, C., Olausson, B., Szamosi, J., & Eriksson, H. (2011). Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder: an analysis of pooled data from three 8-week placebo-controlled studies. Hum Psychopharmacol, 26(8), 614-628. doi:10.1002/hup.1256

Stolpmann, G., Stolpmann, G., Muller, J. L., Petersen, K. U., Batra, A., Haupt, M., . . . Wobrock, T. Themenschwerpunkt: Teilgebiete der Psychiatrie und Psychotherapie: Bekanntes und neue Entwicklungen (Mit 6 Einzelbeitragen).

Strawbridge, R., Carter, B., Marwood, L., Bandelow, B., Tsapekos, D., Nikolova, V. L., . . . Young, A. H. (2019). Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis. Br J Psychiatry, 214(1), 42-51. doi:10.1192/bjp.2018.233

Stubner, S., Grohmann, R., Engel, R., Bandelow, B., Ludwig, W. D., Wagner, G., . . . Ruther, E. (2004). Blood dyscrasias induced by psychotropic drugs. Pharmacopsychiatry, 37 Suppl 1, S70-78. doi:10.1055/s-2004-815513

Trenckmann, U., & Bandelow, B. (1999). Psychiatrie und Psychotherapie. Darmstadt: Steinkopff.

Trenckmann, U., & Bandelow, B. (2002). Psychiatrie und Psychotherapie in Deutsch, Polnisch, Russisch und Türkisch. Darmstadt: Steinkopff.

Trivedi, M. H., Bandelow, B., Demyttenaere, K., Papakostas, G. I., Szamosi, J., Earley, W., & Eriksson, H. (2013). Evaluation of the effects of extended release quetiapine fumarate monotherapy on sleep disturbance in patients with major depressive disorder: a pooled analysis of four randomized acute studies. Int J Neuropsychopharmacol, 16(8), 1733-1744. doi:10.1017/S146114571300028X

Tural, U., Fidane, H., Alkin, T., & Bandelow, B. (2002). Assessing the severity of panic disorder and agoraphobia: validity, reliability and objectivity of the Turkish translation of the Panic and Agoraphobia Scale (P&A). J Anxiety Disord, 16(3), 331-340.

Tural, Ü., Fidaner, H., Alkın, T., & Bandelow, B. (2000). Panik Agorafobi Ölçeğinin güvenirlik ve geçerliği. Turk Psikiyatri Derg, 11, 29-39.

Uhlmann, A., Bandelow, B., Stein, D. J., Bloch, S., Engel, K. R., Havemann-Reinecke, U., & Wedekind, D. (2018). Grey matter structural differences in alcohol-dependent individuals with and without comorbid depression/anxiety-an MRI study. Eur Arch Psychiatry Clin Neurosci. doi:10.1007/s00406-018-0870-x

Van Ameringen, M., Allgulander, C., Bandelow, B., Greist, J. H., Hollander, E., Montgomery, S. A., . . . World Council of, A. (2003). WCA recommendations for the long-term treatment of social phobia. CNS Spectr, 8(8 Suppl 1), 40-52.

Voderholzer, U., Hohagen, F., Adli, M., Bandelow, B., Barton, B., Batra, A., . . . Deutsche Gesellschaft für Psychiatrie und Psychotherapie Psychosomatik und Nervenheilkunde. (2017). Therapie psychischer Erkrankungen State of the Art 2018 (13. Auflage ed.).

Völker, S., Knopp, G., Trampe, A., Bandelow, B., Hanemann, B., Haag-Kirchner, P., & Fless, F. (2009). Idole: Annäherung an einen vagen Begriff. ISBN 978-3938832516. München: Edition Minerva.

Weber, H., Scholz, C. J., Domschke, K., Baumann, C., Klauke, B., Jacob, C. P., . . . Reif, A. (2012). Gender differences in associations of glutamate decarboxylase 1 gene (GAD1) variants with panic disorder. PLoS One, 7(5), e37651. doi:10.1371/journal.pone.0037651

Wedekind, D., & Bandelow, B. (2004). [Anxiety-ridden patients in the doctor’s office]. MMW Fortschr Med, 146(33-34), 24-26.

Wedekind, D., & Bandelow, B. (2005). [The alpha2delta subunit of the voltage-dependent calcium channel. A new pharmaceutical target for psychiatry and neurology]. Nervenarzt, 76(7), 888-891. doi:10.1007/s00115-005-1940-7

Wedekind, D., & Bandelow, B. (2009). Quantifizierungs-Inventar für somatoforme Syndrome QUISS ; Manual. Göttingen [u.a.]: Hogrefe.

Wedekind, D., & Bandelow, B. (2015). Psychiatrische Notfälle. In S. Blaschke & F. Walcher (Eds.), SOP Handbuch Interdisziplinäre Notaufnahme (pp. 227-250). Berlin: Medizinisch Wissenschaftliche Verlagsgesellschaft.

Wedekind, D., Bandelow, B., Broocks, A., Hajak, G., & Ruther, E. (2000). Salivary, total plasma and plasma free cortisol in panic disorder. J Neural Transm (Vienna), 107(7), 831-837. doi:10.1007/s007020070062

Wedekind, D., Bandelow, B., Fentzahn, E., Trumper, P., & Ruther, E. (2007). The quantification inventory for somatoform syndromes (QUISS): a novel instrument for the assessment of severity. Eur Arch Psychiatry Clin Neurosci, 257(3), 153-163. doi:10.1007/s00406-006-0700-4

Wedekind, D., Bandelow, B., Heitmann, S., Havemann-Reinecke, U., Engel, K. R., & Huether, G. (2013). Attachment style, anxiety coping, and personality-styles in withdrawn alcohol addicted inpatients. Subst Abuse Treat Prev Policy, 8(1), 1. doi:10.1186/1747-597X-8-1

Wedekind, D., Bandelow, B., & Ruther, E. (2005). [Pharmacotherapy in personality disorders]. Fortschr Neurol Psychiatr, 73(5), 259-267. doi:10.1055/s-2004-830107

Wedekind, D., Broocks, A., Weiss, N., Engel, K., Neubert, K., & Bandelow, B. (2010). A randomized, controlled trial of aerobic exercise in combination with paroxetine in the treatment of panic disorder. World J Biol Psychiatry, 11(7), 904-913. doi:10.3109/15622975.2010.489620

Wedekind, D., Broocks, A., Weiss, N., Rotter-Glattkowski, P., Engel, K., Neubert, K., & Bandelow, B. (2007). Controlled study for effectiveness of sport vs. relaxation training in combination with paroxetine vs. Placebo in the treatment of the panic disorder. Nervenarzt, 78, 510-510.

Wedekind, D., Engel, K., & Bandelow, B. (2007). [Early detection of anxiety disorders]. MMW Fortschr Med, 149(13), 32-35.

Wedekind, D., Engel, K., & Bandelow, B. (2008). [Social anxiety disorder–diagnostics and treatment options]. Fortschr Neurol Psychiatr, 76(10), 616-620; quiz 621-614. doi:10.1055/s-2008-1038201

Wedekind, D., Gruber, O., Obst, K., Dechent, P., Engel, K. R., Ulrich, K., & Bandelow, B. (2011). Functional Mri Activation in Response to Panic-Specific, Non-Panic Aversive, and Neutral Imagery in Patients with Panic Disorder and Healthy Controls. European Psychiatry, 26.

Wedekind, D., Herchenhein, T., Kirchhainer, J., Bandelow, B., Falkai, P., Engel, K., . . . Havemann-Reinecke, U. (2010). Serotonergic function, substance craving, and psychopathology in detoxified alcohol-addicted males undergoing tryptophan depletion. J Psychiatr Res, 44(16), 1163-1169. doi:10.1016/j.jpsychires.2010.04.002

Wedekind, D., Herchenhein, T., Kirchhainer, S., Bandelow, B., Engel, K., Malchow, B., . . . Havermann-Reinecke, U. (2008). Serotonergic function, substance craving, and psychopathology in detoxified alcohol addicted males undergoing tryptophane depletion. International Journal of Neuropsychopharmacology, 11, 241-241.

Wedekind, D., Sprute, A., Broocks, A., Huther, G., Engel, K., Falkai, P., & Bandelow, B. (2008). Nocturnal urinary cortisol excretion over a randomized controlled trial with paroxetine vs. placebo combined with relaxation training or aerobic exercise in panic disorder. Curr Pharm Des, 14(33), 3518-3524.

Wiltfang, J., Schenk-Dapra, B., Stiens, G., Bleich, S., Bandelow, B., Muller, P., . . . Ruther, E. (2001). Clozapine-associated elevation of plasma cholinesterase. Eur Arch Psychiatry Clin Neurosci, 251(6), 269-271.

Wittchen, H. U., Linden, M., Schwarzer, W., Riemann, D., Boerner, R. J., & Bandelow, B. (2001). [Generalized anxiety disorders (GAD)–a neglected illness? Background und aims of the GAD-P study]. Fortschr Med Orig, 119 Suppl 1, 1-4.

Wobrock, T., Bandelow, B., Reinecke, U. H., & Wedekind, D. (2010). Update psychiatry – alcohol addiction anxiety disorders major-depressive disorder schizophrenia. Nervenheilkunde, 29(11), 734-+.

Wolff-Menzler, C., & Bandelow, B. (2010). [The weeping patient]. MMW Fortschr Med, 152(38), 29-30.

Zerr, I., Bandelow, B., Wedekind, D., Schneider, A., Radenbach, K., Wiltfang, J., & Bähr, M. (2016). Neuropsychiatrische Erkrankungen und Demenzen: ein interdisziplinärer Ansatz. [Neuropsychiatric Disorders and Dementia: An Interdisciplinary Concept]. Aktuelle Neurologie, 43(06), 369-371. doi:10.1055/s-0042-106719